Fused tricyclic mGluR1 antagonists as therapeutic agents
US7767815B2 · kind B2 · utility
0Cited by
1References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 16, 2006 |
| Grant date | Aug 3, 2010 |
| Priority date | — |
| Expiry date | May 21, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.